Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No matter what there is always -ve spin...it all matters when they submit THE APPLICATION FOR APPROVAL. Anyway one good way look at it is we are getting the exposure
DCVAX-L in BBC News!!
From Stockwits:
https://www.bbc.com/news/uk-england-derbyshire-66445546
Search by DCVAX -mentioned in the Paragraph
Cs are potent anti-tumoral cells that generate an immune response through presenting tumor antigens to T cells; due to this ability, DC vaccines, such as DCVax-L, are a major focus of attention for immunotherapy of gliomas21. B cells are also efficient antigen-presenting cells that act to enhance clonal expansion of tumor-specific T lymphocytes, boosting anti-tumor response22. Other anti-tumoral cells include neutrophils, which are members of the innate immune system. Their presence within the TIME has been associated with the development of resistance to anti-VEGF therapies such as bevacizumab and higher rate of metastasis23.
Congrats Longs - Nature Published DCVAX article - Its highly prestigous publication!!
https://www.nature.com/articles/s41698-023-00413-9
I don't know whether its already posted here - Bioservices-Inc-of-374670-shares-of-Northwest-Bio
https://www.macroaxis.com/invest/story/NWBO/24269742/Purchase-by-Cognate-Bioservices-Inc-of-374670-shares-of-Northwest-Bioth
Kazia Therapeutics shares are trading lower after the company announced it's GBM AGILE pivotal study for paxalisib did not meet the pre-defined criteria for continuing to a second stage.
No matter what this is +ve news and this should not be trading at this level!
Exactly!
Don't you know that tote Bag is a Great Scientist lol! I am really wondering how much impact he has on an investment community.
UCLA updated
“UCLA is one of the top five brain tumor research programs in the country...We were the first program to use certain types of targeted therapies, including a brain tumor vaccine (DCVax).” I believe this is a new language on the UCLA website"
“UCLA is one of the top five brain tumor research programs in the country...We were the first program to use certain types of targeted therapies, including a brain tumor vaccine (DCVax).” I believe this is new language on the UCLA website. $NWBO #DCVAXhttps://t.co/xiyQepCtru
— Hope4Patients (@Dave46217976) June 16, 2022
Because , IMO these are all well thought out and planned -
1. The Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, will analyze the data with the Statisticians in preparation for public announcement - NYAS + ASCO 2022 and scientific publication.
2. Next will be the publication since the data has a strong backing and was released by the medical community.
3. What happened on May 10th - was expected by the NWBO management - they know the shorts will bite their bait. But this was minimal damage...
4. Damage control by yesterday's event at ASCO...
Thank you for the clarification!
NVCR is on fire for the past few days because they Announced Clinical Collaboration with MERCK to Evaluate Tumor Treating Fields Together with KEYTRUDA(R) (pembrolizumab) in Newly Diagnosed Glioblastoma
Why NWBO didn't announce as they also trying their DCVAX with KEYTRUDA!
I cant understand this management!
NVCR Flying!!
Count me in...
Maybe results will be announced @ Journal this week or tomorrow ...that seems like a plan!
No Idea - I happened to look at SWits today morning ...
If you read the article seems like they know what they are talking about.
Yes someone posted on StockTwits Today!
From Houston Methodist Leading Medicine - Don't know if it is already posted!
https://www.houstonmethodist.org/738_servicesandspecialties/2044_servicesandspecialities_neurologyandneurosurgery/2181_servicesandspecialities_locations/2183_servicesandspecialities_neurologicalinstitutetexasmedicalcenterhouston/2185_servicesandspecialities_clinicalprograms/609_forhealthcareprofessionals_kennethrpeakbrainandpituitarytreatmentcenter/newpage_peakcenter_clinicaltrial_intro/newpage_peakcenter_clinical-trials_dc-vax/
oops my bad! My AMTD screen got updated today!
News Out!
NEWS out - Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO
First, a license to work with human tissues for medical products at Sawston has been issued by the UK Human Tissue Authority (HTA) to the Company's contract manufacturer and operator of the facility, Advent BioServices. Second, the comprehensive regulatory inspection of the facility has been conducted by the UK Medicines and Health Products Regulatory Authority ("MHRA").
In the UK, an HTA license is required for the collection, processing and storage of human tissues and cells for medical purposes. This includes the tumor tissues used to prepare the lysate for DCVax-L products, and the immune cells that comprise the active ingredient of DCVax-L. Obtaining such a license requires an application, inspection and certification process. This process has now been completed and the HTA license allowing the relevant activities to be conducted at Sawston for DCVax-L has been issued.
The Sawston facility must also be certified and licensed by MHRA in order to be able to manufacture products such as DCVax-L. The process involves an extensive application process, comprehensive inspection of all aspects of the physical facility, its construction and equipment, and all aspects of the facility's operations, including all operating systems, flow of materials and activities, sterility, quality control, staffing and other factors. It also includes extensive scrutiny of the quality management system that comprises approximately 1,000 regulatory documents, including standard operating procedures (SOPs) for the facility and for the product, validation records, data from practice manufacturing runs and other required documents.
Intensive preparations have been under way all year for this comprehensive inspection. A detailed application package and data were submitted to MHRA to qualify for the inspection. The original inspection timing was delayed by MHRA due to their caseload; however, the week-long onsite review by two MHRA inspectors was recently completed. The final phase of the process involves receiving an official MHRA inspection report and taking any responsive actions that may be required. The Company currently anticipates that this process will be completed before year-end.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax(R) dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax(R)-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial reached data lock and the Company is actively continuing to move toward announcement of top line data. The Company has also developed DCVax(R)-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS
Dave Innes Les Goldman
804-513-4758 dinnes@nwbio.com 240-234-0059 lgoldman@nwbio.com
https://c212.net/c/img/favicon.png?sn=NY56307&sd=2021-10-28
View original content:https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-hta-license-issued-and-mhra-inspection-conducted-for-sawston-uk-facility-301411227.html
SOURCE Northwest Biotherapeutics
https://rt.prnewswire.com/rt.gif?NewsItemId=NY56307&Transmission_Id=202110281142PR_NEWS_USPR_____NY56307&DateId=20211028
NEWS out - Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
Guys need help... I have tons of shares of GBDX - Need to get rid of it. AMTD asking me to fill SEC -144 form which requires a Company's IRS Identification number which can be obtained from the company's past filings.. I couldn't able to find any past filings... Incase if any anyone has it please kindly post it. Please help me out!
Amtd don't let me put sell order - it says it's restricted...I need to talk to them, they will be open at 9 AM
Thank You John!
Impossible, A sweat factory can't become one, anyway, they are trying hard. You can see the impact of it in or elections today. They bought everyone out!
LP please release the KRAKEN! MAKE NWBO GREAT AGAIN(MNGA)
Very well said, Bro! Facts tells truth! The facts are -
it's a 13-year study. People survived and lived longer. It cures cancer - period.
Let assume if a big fish is involved like MRK, then anything is possible...
Thanks! They did a recent policy change which I am not aware of.
It seems like we are back to Business @ Stockwits...I remember when I first took the position before it got delisted in 2016.
Wrong! Not Pink Sheets...You want to twist any +ve to -ve, Well go and take a look at the history of NWBO @ Stockwits the last post was
markstachowski
12/30/16, 10:51 AM
until Yesterday
Famdeal1
11/24/20, 06:18 PM
Weird how come? They don't entertain PK Sheets stocks!! The last post was in StockTwits in 2016...I will take this as +VE development!!
Hey 10Baggerz... this is open MB..one can post what they are tried to get the information...which would help! We all here for the same purpose...to make $$$...
Thank you for your effort!
Maybe we will see 8K instead of 10Q - fingers crossed!
The main Intriguing part is 10Q delayed beyond the due date and of course TLD.
Let say If BO in the works - do they still need to file 10Q?
Good Catch Dude- "PM"
That's not going to happen- History is evident. You can't win by cheating! It's a deep state everyone is involved but it's 2020 - everything will balance out!
It's a bias that this post will be deleted!
Very much True!
102K on Bid!
Its Accumulation- I am seeing this pattern since last week on Bid X Ask...